$1.47+0.09 (+6.16%)
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
Filana Therapeutics, Inc. in the Healthcare sector is trading at $1.47. The stock is currently near its 52-week low of $1.35, remaining 40.0% below its 200-day moving average. Technical signals show oversold RSI of 28 and bearish MACD signal, explaining why FLNA maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's dise...